Nucleotide and protein sequences of vertebrate delta genes...

Details Nucleotide and protein sequences of vertebrate delta genes... Nucleotide and protein sequences of vertebrate delta genes...

2011-04-19

2011-04-19

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019300, C530S387100, C530S387700, C530S388100, C530S388150, C530S388220

Reexamination Certificate

active

07928071

ABSTRACT:
The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided. In specific examples, isolated Delta genes, fromXenopus, chick, mouse, and human, are provided.

REFERENCES:
patent: 5637471 (1997-06-01), Artavanis-Tsakonas et al.
patent: 5648464 (1997-07-01), Artavanis-Tsakonas et al.
patent: 5750652 (1998-05-01), Artavanis-Tsakonas et al.
patent: 5780300 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5786158 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5789195 (1998-08-01), Artavanis-Tsakonas et al.
patent: 5849869 (1998-12-01), Artavanis-Tsakonas et al.
patent: 5856441 (1999-01-01), Artavanis-Tsakonas et al.
patent: 5869282 (1999-02-01), Ish-Horowicz et al.
patent: 6004924 (1999-12-01), Ish-Horowicz et al.
patent: 6083904 (2000-07-01), Artavanis-Tsakonas et al.
patent: 6090922 (2000-07-01), Artavanis-Tsakonas et al.
patent: 6121045 (2000-09-01), McCarthy et al.
patent: 6149902 (2000-11-01), Artavanis-Tsakonas et al.
patent: 6337387 (2002-01-01), Sakano et al.
patent: 6436650 (2002-08-01), Artavanis-Tsakonas et al.
patent: 6692919 (2004-02-01), Artavanis-Tsakonas et al.
patent: 6703489 (2004-03-01), Artavanis-Tsakonas et al.
patent: 6783956 (2004-08-01), Ish-Horowicz et al.
patent: 7118890 (2006-10-01), Ish-Horowicz et al.
patent: 2004/0058443 (2004-03-01), Artavanis-Tsakonas et al.
patent: 2004/0242482 (2004-12-01), Artavanis-Tsakonas et al.
patent: 2005/0112121 (2005-05-01), Artavanis-Tsakonas et al.
patent: 2005/0158859 (2005-07-01), Artavanis-Tsakonas et al.
patent: 2007/0003983 (2007-01-01), Artavanis-Tsakonas et al.
patent: 0 861 894 (1998-09-01), None
patent: WO 92/19734 (1992-11-01), None
patent: WO 93/12141 (1993-06-01), None
patent: WO 94/07474 (1994-04-01), None
patent: WO 96/27610 (1996-09-01), None
patent: WO 97/01571 (1997-01-01), None
patent: WO 97/11716 (1997-04-01), None
patent: WO 97/18822 (1997-05-01), None
patent: WO 97/19172 (1997-05-01), None
patent: WO 97/45143 (1997-12-01), None
patent: WO 98/17793 (1998-04-01), None
patent: WO 98/20142 (1998-05-01), None
patent: WO 98/45434 (1998-10-01), None
patent: WO 98/51799 (1998-11-01), None
patent: WO 00/02897 (2000-01-01), None
Noguer-Troise et al., Blockade of DII4 inhibits tumor growth by promoting non-productive angiogenesis, Dec. 2006, Nature, vol. 444, pp. 1032-1037.
Ridgway et al., Inhibition of DII4 signaling inhibits tumor growth by deregulating angiogenesis, Dec. 2006, Nature ,vol. 444, pp. 1083-1087.
Patel et al., 2005, “Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function,” Cancer Res. 65(19):8690-8697.
Wu et al., Stabilizing Receptor Quiescence with Synthetic Antibodies Enables Precise Control of Notch Signaling In Vivo, manuscript submitted.
Büchler et al., 2005, “The Notch Signaling Pathway Is Related to Neurovascular Progression of Pancreatic Cancer,” Ann. Surg. 242:791-801.
Purow et al., 2005, “Expression of Notch-1 and Its Ligands, Delta-Like-1 and Jagged-1, Is Critical for Glioma Cell Survival and Proliferation,” Cancer Res. 65(6):2353-2363.
Li et al., 2008, “Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3,” J. Biol. Chem.
Kogoshi et al., 2007, “γ-Secretase Inhibitors Suppress the Growth of Leukemia and Lymphoma Cells,” Oncology Reports 18:77-80.
Park et al., 2006, “Notch3 Gene Amplification in Ovarian Cancer,” Cancer Res. 66:6312-6318.
Konishi et al., 2007, “γ-Secretase Inhibitor Prevents Notch3 Activation and Reduces Proliferation in Human Lung Cancers,” Cancer Res. 67:8051-8057.
Krop et al., 2006, Abstract 6097, Breast Cancer Research and Treatment 100: Supplement 1.
Farnie et al., 2007, “Mammary Stem Cells and Breast Cancer-Role of Notch Signalling,” Stem Cell Rev. 3:169-175.
Farnie et al., 2007, “Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways,” J. Natl. Cancer Inst. 99:616-627.
Dontu et al., 2004, “Role of Notch Signaling in Cell-Fate Determination of Human Mammary Stem/Progenitor cells,” Cancer Res. 6:R605-R615.
Politi et al., 2004, “Notch in Mammary Gland Development and Breast Cancer,” Sem. Cancer Biol. 14:341-347.
Reedijk et al., 2005, “High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival,” Cancer Res. 65(18):8530-8537.
Nam et al., 2002, “Notch Signaling As a Therapeutic Target,” Curr. Opin. Chem. Biol. 6:501-509.
Jundt et al., 2002, “Activated Notch 1 Signaling Promotes Tumor Cell Proliferation and Survival in Hodgkin and Anaplastic Large Cell Lymphoma,” Blood 99(9):3398-3404.
Miele et al., 2006, “NOTCH Signaling as a Novel Cancer Therapeutic Target,” Curr. Cancer Drug Targets 6:313-323.
Jang et al., 2000, “Notch Signaling As a Target in Multimodallty Cancer Therapy,” Curr. Opin. Mol. Therapeutics 2(1):55-65.
Veeraraghavalu et al., 2004, “Papillomavirus-M Ediated Neoplastic Progression Is Associated With Reciprocal Changes in Jagged1 and Manic Fringe Expression Linked to Notch Activation,” J. Virology 78:8687-8700.
Kiaris et al., 2004, “Modulation of Notch Signaling Elicits Signature Tumors and Inhibits Hras1-Induced Oncogenesis in the Mouse Mammary Epithelium,” Am. J. Pathology 165:695-705.
Hoek et al., 2004, “Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas,” Cancer Research 64:5270-5282.
Hayashi et al., 2004, “Expression Failure of the Notch Signaling System Is Associated with the Pathogenesis of Testicular Germ Cell Tumor,” Tumor Biology 25:99-105.
Dang et al., 2003, “Constitutive Activation of Notch3 Inhibits Terminal Epithelial Differentiation in Lungs of Transgenic Mice,” Oncogene 22:1988-1997.
Santagata et al., 2004, “JAGGED1 Expression Is Associated with Prostate Cancer Metastasis,” Cancer Res. 64:6854-6857.
Harper et al., 2002, “Developmental Biology: Frontiers for Clinical Genetics,” Clin. Genet. 64:461-472.
Office Action dated Mar. 15, 1999 for U.S. Appl. No. 08/937,132.
Office Action dated Dec. 7, 1999 for U.S. Appl. No. 08/937,132.
Advisory Action dated Mar. 7, 2001 for U.S. Appl. No. 08/937,132.
Office Action dated Sep. 18, 2001 for U.S. Appl. No. 08/937,132.
Office Action dated Aug. 8, 2002 for U.S. Appl. No. 08/937,132.
Office Action dated Apr. 23, 2002 for U.S. Appl. No. 09/564,504.
Office Action dated Jan. 14, 2003 for U.S. Appl. No. 09/564,504.
Office Action dated Mar. 23, 2001 for U.S. Appl. No. 09/565,115.
Office Action dated Dec. 19, 2001 for U.S. Appl. No. 09/565,115.
Office Action dated Aug. 9, 2007 for U.S. Appl. No. 10/781,060.
Office Action dated May 14, 2008 for U.S. Appl. No. 10/781,060.
Office Action dated Sep. 23, 2009 for U.S. Appl. No. 11/546,583.
Braydich-Stolle et al., 2005, Role of Glial Cell Line-Derived Neurotrophic Factor in Germ-Line Stem Cell Fate, Ann. N.Y. Acad. Sci. 1061:94-99.
Lasky et al., 2005, Notch Signaling, B

Affiliated with

Also associated with

Rating

Nucleotide and protein sequences of vertebrate delta genes... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleotide and protein sequences of vertebrate delta genes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleotide and protein sequences of vertebrate delta genes... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2714508